Of all the subtypes of metastatic breast cancer, metastatic Triple Negative Breast Cancer (TNBC) is the hardest to treat with the worst prognosis. While new advances in the treatment of hormone positive MBC and Her2 MBC have helped some patients live for a number of years, average life expectancy for someone with metastatic TNBC is just 12-18 months.
We started our campaign in Metastatic May with some information about treatment lines and it really caused a bit of a stir, especially on Instagram.
Why? Because people don’t want to think that this disease is going to kill us. We have to remain positive. We have to see the chink of light and I agree we all have to have hope. That was my introduction. We need hope.
In 2018 I was diagnosed with secondary breast cancer in my liver, I was 44.
I knew the survival statistics were grim, so decided from the outset, in order to outlive the 2 to 3-year median I’d have to embrace experimental drugs and treatments.
I made this clear during my first oncology appointment, telling my doctor I was keen to sign up for clinical trials right from the start.
Stage 4 breast cancer with a pacemaker
Most people know someone with a pacemaker, and chances are that person will be elderly. The average age of a first pacemaker implantation in the UK is 72, but pacemakers are actually fitted in people of all ages from newborn babies to the very elderly. I was 39 when I had mine, which was needed as a complication after heart surgery to replace my aortic valve and root.
I remember first hearing about genomics testing for cancer, about a year after my diagnosis of secondary breast cancer. I had failed on every line of treatment I’d been given, was fast running out of options, and looking for a lifeline
Abstract: Despite being the hallmark of cancer that is responsible for the highest number of deaths, very little is known about the biology of metastasis. Metastatic disease typically manifests after
We thought you would like to hear about what it is like to work in metastatic breast cancer research. Here, we chat to Dr Rachel Eyre who works at The
